CCR

Leronlimab (PRO 140), a humanized IgG4 monoclonal antibody, targets CCR5 to combat HIV and cancer.

ML604086 suppresses CCL1 mediated chemotaxis and enhances intracellular Ca2 concentrations.

RS102895 hydrochloride is a potent antagonist of CCR2(IC50 of 360 nM).

CCX140 (CCX140-B) (CCX140-B) is an antagonist of CCR2.

INCB-9471 is a CCR5 antagonist with anti-HIV activity and inhibits the interaction between HIV-1 gp120.

AZ084 is a potent, selective, allosteric, and oral active CCR8 antagonist (Ki: 0.9 nM). It has the potential to treat asthma.

Mogamulizumab is a monoclonal antibody targeting CC chemokine receptor 4 with anticancer effects, used in ATLL and CTCL studies.

CCR2-RA-[R] is a C-C chemokine receptor type 2 (CCR2) allosteric antagonist (IC50: 103 nM).

MK-0812 Succinate is an effective and selective CCR2 antagonist.

J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM).

LM-108 is a monoclonal antibody that targets CCR8. It selectively eliminates tumor-infiltrating regulatory T cells (Treg) and is applicable to gastric cancer research.

NI-0701 is a humanized antibody targeting CCL5/RANTES.

LT166 is a fluorescent ligand for CC chemokine receptor 1 (CCR1) with a dissociation constant (KD) of 1.90 μM.

Emapticap pegol scramble negative control, an oligonucleotide aptamer, serves as the negative control for Emapticap pegol.

CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.

CCR8 agonist1 (Compound 2) is an activator of CCR8 and is applicable in studies related to autoimmune diseases.

ECL1i TFA is an allosteric, selective CCR2 inhibitor. It specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA can interfere with the recruitment of CCR2-positive cells and mitigate the progression of experimental autoimmune encephalomyelitis.

2-Methoxyhydroquinone inhibits MAO-A and MAO-B and reduces TNF-α-induced CCL2 production, a precursor for synthesising the Hsp90 inhibitor Geldanamycin.

Tagmokitug is a humanized IgG1κ monoclonal antibody inhibitor targeting CCR8. It exhibits anti-tumor activity and is applicable in cancer immunotherapy research, including studies on breast cancer, colon cancer, and lung cancer.

PF-232798 is a second generation oral CCR5 antagonist with potent broad-spectrum anti-HIV-1 activity.

Zn-DPA-maytansinoid 1 targets checkpoints, shrinks tumors, and heats TME.

A unique collection of xnum chemokines or chemokine receptors targeted compounds for high throughput and high content screening;

CAP-100 is a monoclonal antibody targeting CCR7. It neutralizes the ligand binding site and signaling of CCR7. This compound effectively inhibits migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples induced by CCR7. CAP-100 can mediate potent tumor cell killing through host immune mechanisms and exhibits favorable toxicity profiles in related hematopoietic cell subsets. It is involved in research on antitumor activity and diseases like chronic lymphocytic leukemia (CLL).

HGS101 is a fully humanized CCR5 monoclonal antibody that exhibits high affinity for CCR5. It binds to the second extracellular loop (ECL-2) and functions as a signaling antagonist. HGS101 restores the inhibitory effect of Maraviroc in Maraviroc-resistant HIV-1 infected PBMCs. In an uninfected simian immunodeficiency virus model of rhesus monkeys, HGS101 shows anti-HIV activity by inhibiting CCR5 signaling.

VZMC013 is a potent chemical probe targeting the MOR-CCR5 heterodimer, effectively inhibiting HIV-1 entry exacerbated by opioid compounds. It exhibits nanomolar binding affinity to both MOR and CCR5, inhibits CCL5-activated calcium mobilization, and significantly enhances anti-HIV-1BaL activity compared to previously reported bivalent ligands. In TZM-bl cells co-expressing CCR5 and MOR, VZMC013 demonstrates greater inhibition of viral infection than in cells expressing only CCR5. Additionally, VZMC013 blocks HIV-1 entry into peripheral blood mononuclear cells (PBMC) in a concentration-dependent manner and more effectively inhibits opioid-accelerated HIV-1 entry in phytohemagglutinin-activated PBMC than in opioid-free environments.

CCR2 antagonist 1 is a high-affinity and long-residence-time antagonist of CCR2 (Ki: 2.4 nM).

MLN-3897 TFA is a potent CCR1 antagonist that inhibits the binding of 125I-MIP-1α to THP-1 cell membranes.

INCB10820 is an efficient and specific dual antagonist of CCR2 and CCR5, with oral bioavailability.

CMKLR1 antagonist 1 (compound S-26d) is a potent, orally active antagonist of the chemokine-like receptor 1 (CMKLR1), exhibiting a pIC50 of 7.44 in hCMKLR1-

LUF7996 is a CCR2-targeting PROTAC degrader with a DC50 of 2.6 μM, designed to degrade CCR2 effectively. It binds simultaneously to CCR2 and the E3 ligase cereblon, demonstrating sustained and concentration-dependent degradation of CCR2. The compound induces CCR2 degradation via the lysosomal pathway and effectively inhibits monocyte migration in vitro.

WAY-639418 has potential anti-inflammatory and anti-HIV activity and can be used to study CCR5-mediated inflammatory and immunomodulatory diseases.

Orally active CCR4 antagonist with piperidinyl-azetidine; IC50: 22 nM (calcium flux), 50 nM (CTX); antitumor effects.

Aplaviroc, a potent CCR5 inhibitor, binds selectively, blocking HIV entry and specific monoclonal antibody attachment in vitro.

HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. It exhibits potent antiviral activity against various CCR5-tropic HIV-1 strains, including those resistant to other treatments (such as Maraviroc-resistant strains). HGS004 is applicable for research in HIV-1 infection.

Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study of

INCB 3284 dimesylate: oral CCR2 antagonist, blocks MCP-1/hCCR2 binding (IC50: 3.7 nM), potential in acute liver failure research.

GSK163929 (compound 122) is an orally active CCR5 antagonist with anti-HIV properties and demonstrates low inhibitory potency against hEGR. Administered at a dosage of 2000 mg/kg/day (i.v., 7 d), it shows no adverse effects in rats, and at 250 mg/kg/day (i.v., 7 d), it is similarly non-toxic in dogs.

Bertilimumab (CAT 213; iCo-008), a human monoclonal antibody that targets eotaxin-1 (CCL11), shows promise in the research of allergic disorders [1].

CCR6 antagonist2 (Compound 20c) acts as a CCR6 antagonist with a Ki of 1.1 nM. It inhibits CCL20-induced calcium influx with an IC50 of 4.9 nM and suppresses the chemotactic migration of CCR6+ T cells with an IC50 of 190 nM.

CCR6 antagonist 1 blocks CCL20/CCR6, aiding autoimmune and IBD research.

CKLF1-C27 peptide activates ERK1/2 via CCR4, competes with CKLF1, promotes HUVEC growth, and has psoriasis research potential.

Orally active CCR4 antagonist 3 hydrochloride with potent selectivity, IC50s: 22/50 nM; has antitumor properties.

TBK1degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. It effectively inhibits cyst growth, reduces inflammation, and lowers levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1degrader-4 shows potential for research in autosomal dominant polycystic kidney disease (ADPKD).

BMS-753426 is a potent and orally bioavailable antagonist of CCR2 .

INCB3344 is a potent CCR2 antagonist. INCB3344 R-isomer is the R-isomer of INCB3344.

CHS-114 (SRF-114) is a fully human IgG1 antibody targeting the (CCR8) receptor. It shows potential for research in head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can be referred to as HumanIgG1kappa, Isotype Control.

CCR6 inhibitor 1 selectively blocks CCR6 (0.45 nM in monkeys, 6 nM in humans), aiding in vitro/vivo disease studies.

SQA1 is a derivative of a phthalamide (SQA) and acts as a CCR6 antagonist with a Kd of 250 nM, as well as a CXCR2 inhibitor. It occupies an intracellular pocket that overlaps with the G protein binding site, stabilizing the pocket's closed conformation.

Met-RANTES (human) acetate is the acetate salt form of Met-RANTES (human). It acts as an antagonist for CCR1 and CCR5 receptors. This compound inhibits the human chemokines MIP-1α and MIP-1β, with respective IC50 values of 5 and 2 nM. Additionally, Met-RANTES (human) acetate reduces bone destruction and alleviates adjuvant-induced arthritis (AIA) in rats.

RAP-103 is an orally active CCR antagonist that effectively protects synapses by inhibiting and reversing cytoskeletal changes induced by PrPC/NOX signaling. RAP-103 is applicable for research in Alzheimer's disease (AD).